At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 141 enrolled
Drug / intervention
Entinostat +2 moredrug
Likely dose
Erlotinib 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study With a Lead in Phase of Erlotinib With or Without SNDX-275 in Patients With NSCLC After Failure In Up to Two Prior Chemotherapeutic Regimens for Advanced Disease
In Brief
A Phase 2 clinical trial evaluating Entinostat, Placebo, and 1 other intervention for Non-Small-Cell Lung Carcinoma and Carcinoma, Non-Small Cell Lung. Completed, enrolled 141 participants across 30 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of entinostat in combination with erlotinib in the treatment of Advanced Non-Small Cell Lung Cancer (NSCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedJan 2008
Primary CompletionFeb 2010
Study CompletionFeb 2012
TodayJul 2026
First PostedJan 28, 2008
Enrollment StartJan 8, 2008
Primary CompletionFeb 4, 2010
Study CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 18.4 years ago
Interventions
Entinostatdrug
Entinostat tablets on Days 1 and 15 of a 28-day cycle.
Placebodrug
Placebo-matching entinostat tablets on Days 1 and 15 of a 28-day cycle.
Erlotinibdrug
Erlotinib 150 mg tablets once daily.